This also explains why the overexpression DTL phenotype in the HCC cohort is significantly correlated with these clinical features (T stages and pathological stage), and patients whose tumors overexpressed the DTL gene, accompanying a higher proportion of somatic mutations (e.g., TP53), had much worse clinical outcomes than those whose tumors did not across HCC. Here, TP53 is linked to hepatocellular carcinoma.